Personalised therapy in follicular lymphoma – is the dial turning?

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2023-07-22 DOI:10.1002/hon.3205

Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne-Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun

{"title":"Personalised therapy in follicular lymphoma – is the dial turning?","authors":"Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne-Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun","doi":"10.1002/hon.3205","DOIUrl":null,"url":null,"abstract":"<p>Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3205","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3205","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.

查看原文本刊更多论文

滤泡性淋巴瘤的个性化治疗--表盘转动了吗？

滤泡淋巴瘤是最常见的非霍奇金淋巴瘤，约占西方国家新诊断出的非霍奇金淋巴瘤的20%-25%。虽然疗效大多良好，但临床表型的范围包括疗效明显较差的高危人群。这篇综述讨论了风险分层和治疗方法的最新进展，从局限期和晚期滤泡性淋巴瘤的前期治疗，到复发、难治性疾病的越来越多的选择，以及如何从个性化角度进行治疗的观点。在如何根据不同的风险为患者精确、前瞻性地选择最佳治疗方法方面仍存在明显差距，但随着对这些不同表型的生物学特性的进一步了解，以及基于成像和生物标志物的工具的日益完善，这些差距有望逐渐缩小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.